News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
250,227 Results
Type
Article (15333)
Company Profile (41)
Press Release (234853)
Section
Business (77179)
Career Advice (951)
Deals (14367)
Drug Delivery (20)
Drug Development (33358)
Employer Resources (24)
FDA (5321)
Job Trends (5558)
News (130763)
Policy (10398)
Tag
Academia (628)
Africa (258)
Allergies (17)
Alliances (12445)
Alzheimer's disease (343)
Antibody-drug conjugate (ADC) (17)
Approvals (5299)
Arizona (57)
Asia (14453)
Australia (2300)
Bankruptcy (296)
Best Places to Work (4169)
Biotechnology (27)
C2C Services and Suppliers (28338)
California (521)
Canada (302)
Cancer (121)
Career advice (878)
Cell therapy (25)
China (32)
Clinical research (26967)
Collaboration (22)
Colorado (18)
Connecticut (27)
COVID-19 (805)
Cystic fibrosis (21)
Data (73)
Diabetes (20)
Diagnostics (1894)
Earnings (49952)
Employer resources (19)
Europe (34257)
Events (42395)
FDA (5374)
Florida (71)
Funding (22)
Gene therapy (19)
Georgia (16)
GLP-1 (159)
Government (1273)
Healthcare (6208)
Hotbed/Location (169966)
Idaho (16)
Illinois (61)
Indiana (51)
Infectious disease (814)
Inflammatory bowel disease (17)
Interviews (184)
IPO (8115)
Job creations (1413)
Job search strategy (673)
Kansas (38)
Layoffs (106)
Legal (2098)
Liver cancer (18)
Lung cancer (28)
Maine (32)
Manufacturing (27)
Maryland (90)
Massachusetts (448)
Medical device (3890)
Medtech (3890)
Mergers & acquisitions (6001)
Metabolic disorders (74)
Michigan (30)
Minnesota (78)
Neuroscience (370)
New Hampshire (16)
New Jersey (172)
New York (190)
NextGen Class of 2024 (1605)
Non-profit (1108)
North Carolina (171)
Northern California (263)
Obesity (43)
Ohio (23)
Opinion (45)
Peanut (15)
Pennsylvania (187)
People (11183)
Phase I (7119)
Phase II (11453)
Phase III (9944)
Pipeline (76)
Postmarket research (1437)
Preclinical (3011)
Rare diseases (43)
Real estate (1593)
Regulatory (7295)
Reports (19)
Research institute (569)
Resumes & cover letters (122)
South America (418)
Southern California (219)
Startups (801)
Texas (57)
United States (2523)
Vaccines (159)
Washington State (115)
Weight loss (38)
Date
Last 7 days (175)
Last 30 days (1011)
Last 365 days (14043)
2024 (9165)
2023 (14737)
2022 (18193)
2021 (20284)
2020 (17574)
2019 (15072)
2018 (10207)
2017 (9426)
2016 (8468)
2015 (10687)
2014 (7582)
2013 (5571)
2012 (6068)
2011 (6746)
2010 (5751)
250,227 Results for "11".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
DermTech Files for Voluntary Chapter 11 Protection
DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.
June 18, 2024
·
5 min read
BioMidwest
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.
July 1, 2024
·
9 min read
IRLAB Participates in Stora Aktiedagarna - June 11, 2024
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will give a presentation at Stora Aktiedagarna in Stockholm on June 11-12.
June 11, 2024
·
1 min read
Deals
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
Elicio Therapeutics, Inc. today announced the pricing of an approximately $11.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and accompanying common warrants to purchase common stock, before deducting underwriting discounts and commissions and estimated offering expenses payable by Elicio.
June 28, 2024
·
5 min read
Drug Development
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
The New England Journal of Medicine has published results from a positive phase 3 study of Dupixent in children aged one to 11 years with eosinophilic esophagitis.
June 26, 2024
·
15 min read
Genetown
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Inozyme Pharma, Inc. announced a data presentation and sponsored symposium at the 11th International Conference on Children’s Bone Health, which is being held June 22-25, 2024, in Salzburg, Austria.
June 21, 2024
·
3 min read
Biotech Bay
Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity
Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.
May 16, 2024
·
3 min read
Biotech Beach
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
ChromaDex Corp. announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, June 11, 2024, at 2:00pm PST.
June 4, 2024
·
2 min read
Job Trends
The Top 11 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
April 3, 2024
·
1 min read
·
Angela Gabriel
Business
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Merck and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
July 1, 2024
·
8 min read
1 of 25,023
Next